Good afternoon :)
Place Order
Add to Watchlist

Shalby Ltd

SHALBY

Shalby Ltd

SHALBY
Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹2,176 cr, stock is ranked 1,011
Moderate RiskStock is 2.85x as volatile as Nifty
199.131.87% (-3.79)
199.131.87% (-3.79)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹2,176 cr, stock is ranked 1,011
Moderate RiskStock is 2.85x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹2,176 cr, stock is ranked 1,011
Moderate RiskStock is 2.85x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
64.322.160.59%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
46.895.970.56%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 1 analyst

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Shalby Limited operates a multi-specialty chain of hospitals. Its hospitals are tertiary care hospitals, which offer quaternary healthcare services

Investor Presentation

View older 

Feb 4, 2025

PDF
View Older Presentations
PE Ratio
88.63
1Y Return
28.44%
Buy Reco %
73.68
PE Ratio
98.40
1Y Return
1.13%
Buy Reco %
86.21
PE Ratio
78.32
1Y Return
51.76%
Buy Reco %
100.00
PE Ratio
89.97
1Y Return
2.39%
Buy Reco %
71.43
PE Ratio
40.74
1Y Return
24.06%
Buy Reco %
66.67
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 15.12%, vs industry avg of 10.01%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 1.28% to 1.5%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 21.56%, vs industry avg of 42.91%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue292.56330.52388.00471.52504.22439.96711.37827.44953.181,093.56
Raw Materialssubtract4.4036.7039.6839.8552.8034.30153.38104.63108.21915.67
Power & Fuel Costsubtract6.797.599.4312.6612.9812.3114.4916.2519.70
Employee Costsubtract28.9238.9045.0864.6065.5056.96114.74143.64155.44
Selling & Administrative Expensessubtract14.8117.5820.5619.5921.0413.6136.8961.3066.75
Operating & Other expensessubtract179.93151.51184.31242.07251.75226.39262.32340.92405.03
Depreciation/Amortizationsubtract11.3316.7022.8633.1736.0236.8042.8748.0952.2465.13
Interest & Other Itemssubtract10.4511.0412.379.187.414.547.5310.5617.6234.51
Taxes & Other Itemssubtract-1.6620.8014.3518.7329.1412.6625.0234.3544.1244.41
EPS4.303.404.032.932.553.925.016.297.833.15
DPS0.000.000.000.500.501.001.001.201.201.20
Payout ratio0.000.000.000.170.200.250.200.190.150.38

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

May 30PDF
Feb 3PDF
Dec 2PDF
Oct 28PDF
FY 2023

Annual report

PDF

Investor Presentation

May 18PDF
Jan 17PDF
Oct 18PDF
Jul 26PDF
FY 2024

Annual report

PDF

Investor Presentation

Jul 20PDF
FY 2025

Annual Report Pending

Investor Presentation

Feb 4PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CareHospitals & Diagnostic Centres

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Shalby Ltd25.892.160.59%
Max Healthcare Institute Ltd88.6311.150.16%
Apollo Hospitals Enterprise Ltd98.4012.080.26%
Fortis Healthcare Ltd78.325.480.16%

Price Comparison

Compare SHALBY with any stock or ETF
Compare SHALBY with any stock or ETF
SHALBY
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding74.27%0.00%0.14%4.65%20.94%

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Shareholding History

SepDec '23MarJunSepDec '244.11%4.62%4.88%5.35%5.37%4.65%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 1 Mutual Funds holding Shalby Ltd


Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.0003%0.05%-0.00%92/103 (+1)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

SHALBY has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.59%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹5.92 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 19, 2024

Final
Final | Div/Share: ₹1.20

Dividend/Share

1.20

Ex DateEx Date

Sep 19, 2024

Cash Dividend

Ex DateEx DateAug 8, 2023

Final
Final | Div/Share: ₹1.20

Dividend/Share

1.20

Ex DateEx Date

Aug 8, 2023

Cash Dividend

Ex DateEx DateSep 19, 2022

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 19, 2022

Cash Dividend

Ex DateEx DateSep 17, 2021

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 17, 2021

Cash Dividend

Ex DateEx DateSep 4, 2020

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Sep 4, 2020

News & Opinions
Live Market Update
Nifty trades above 23,550; metal shares shine; VIX rallies 3.53%

The domestic equity benchmarks traded with substantial gains in early afternoon trade, following gains in Asian markets. This came after the U.S. paused its planned tariffs on Canada and Mexico, which helped alleviate concerns about a potential global trade war. The Nifty traded above the 23,550 mark. Metal shares advanced after declining in past two consecutive trading sessions. At 12:30 IST, the barometer index, the S&P BSE Sensex, rallied 741.66 points or 0.97% to 77,928.40. The Nifty 50 index advanced 214.70 points or 0.92% to 23,575.75. In the broader market, the S&P BSE Mid-Cap index rose 0.78% and the S&P BSE Small-Cap index added 0.57%. The market breadth was strong. On the BSE, 2,317 shares rose and 1,428 shares fell. A total of 164 shares were unchanged. Derivatives: The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, rallied 3.53% to 14.86. The Nifty 27 February 2025 futures were trading at 23,644.75, at a premium of 69 points as compared with the spot at 23,575.75. The Nifty option chain for the 29 February 2024 expiry showed maximum Call OI of 54 lakh contracts at the 24,000 strike price. Maximum put OI of 61.8 lakh contracts were seen at 23,000 strike price. Buzzing Index: The Nifty Metal index gained 1.58% to 8,283.60. The index fell 2.91% in past two consecutive trading sessions. Vedanta (up 3.52%), Jindal Stainless (up 3.03%), Steel Authority of India (up 2.74%), National Aluminium Company (up 2.53%), Hindustan Copper (up 2.45%), NMDC (up 2.22%), Hindalco Industries (up 2.17%), Ratnamani Metals & Tubes (up 1.81%), Welspun Corp (up 1.52%) and Adani Enterprises (up 1.05%) advanced. Stocks in Spotlight: Shalby slipped 4.17% after the company reported a consolidated net loss of Rs 1.81 crore for Q3 FY25, compared to a net profit of Rs 19.07 crore posted in Q3 FY24. However, revenue from operations jumped 27.6% YoY to Rs 275.63 crore in the quarter ended 31 December 2024. NLC India rallied 9.92% after the company's consolidated net profit surged 166.79% to Rs 668.09 crore on 39.41% rise in revenue from operations to Rs 4,411.41 crore in Q3 FY25 over Q3 FY24. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Shalby slides after reporting net loss of Rs 2 cr in Q3

However, revenue from operations jumped 27.6% YoY to Rs 275.63 crore in the quarter ended 31 December 2024. Profit before tax was at Rs 12.35 crore in the third quarter of FY25, down 59.9% from Rs 30.81 crore posted in the same period a year ago. The company's consolidated EBITDA for Q3 FY25 was Rs 39.3 crore. During the quarter, the company's revenue from the healthcare services segment grew by 27.9% YoY to Rs 248.85 crore, while revenue from its implant manufacturing business increased by 24.4% YoY to Rs 26.77 crore. In Q3 FY25, the company had 646 occupied beds, with an inpatient count (including Day Care) of 22,369, reflecting a 7.9 YoY growth. The average revenue per occupied bed (ARPOB) stood at Rs 42,704, marking a 14.4% YoY increase. Shanay Shah, President, Shalby, said, 'The company has shown a decent consolidated performance in Q3'FY25 with a revenue of 281 crore with growth of 27.4% on y-o-y basis. The major growth has been contributed from our implant business and acquisition of Delhi NCR hospital in current calendar year. I'm pleased to announce that our hospital segment has maintained consistent performance across key operational metrics, witnessing a 7.9% rise in In-patient count (including day care) year-on-year in Q3 FY25. Notably, ARPOB and ALOS stood at Rs 42,704 and 3.62 respectively, in Q3 FY25, compared to Rs. 37,342 and 3.79 in the corresponding quarter of the previous year improved by 14.4% and 4.5% respectively. Our core specialties, including arthroplasty, onco-science, cardiac science, orthopaedics, critical care & general medicine, and neurology, collectively contributed 80% to the revenues in Q3 FY25. On a standalone performance, our revenue has grown by 13.3% to Rs 227 crore and EBITDA has grown marginally by 0.8% to Rs 48.8 crore with the EBITDA margin of 21.5% on YoY basis. Furthermore, our realized return on capital employed from the hospital business stood at 15% in Q3'FY25 on an annualized basis. As of the quarter's close, our net debt balance at the group level amounted to Rs 2,667 million, with a net cash balance of Rs 660 million at the standalone level, reinforcing our ability to support strategic growth initiatives. In January'25, Shalby Bone and Tissue Bank has been successfully inaugurated by our Hon'ble Union Home Minister of India, Shri Amit Shah, at our Krishna Shalby Hospital in Ahmedabad. Shalby has continued to achieve numerous milestones driven by clinical excellence and patient satisfaction, and we take pride in making a positive impact on people's lives.' Deepak Anand, global chief business officer, Shalby, said, During the third quarter of this financial year, our implant business made significant progress, generating revenues of Rs 269 million up by 25% YOY, with contributions from the USA and OUS at 33% and 67% respectively. We are actively focused on bolstering our team with skilled professionals, transitioning our sales mix to retail customers from wholesale, enhancing operational capacity and efficiency, expanding our product pipeline through extensive research and development efforts, and significantly reducing procurement costs. The reception of our Shalby Advanced Technology implants in hospitals across all markets that we have launched has been highly positive, and we have received additional orders from the South Asian market. Our strategic clinical trial agreement with Monogram Technology will also benefit SAT Inc. in expanding and growing internationally in other countries. With our key strategies firmly in place, our team is fully dedicated to executing these plans flawlessly. Shalby is well-positioned to achieve double-digit growth with sustainable profitability while also expanding and deepening our presence by opening up new geographies. These efforts will ultimately drive the creation of sustainable value for all stakeholders at Shalby.' Meanwhile, the company's board has approved the re-appointment of Dr. Vikram Shah as chairman and managing director of the company, based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of shareholders. Shalby is the largest chain of multi-specialty hospitals in Western and Central India. It was founded by arthroplasty specialist, Dr. Vikram Shah. It performs more than 14,000 joint replacement surgeries a year and in the last 29 years, has performed more than 1,75,000 joint replacements. It operates under three main verticals, namely, hospital business, Shalby Orthopedics Centre of Excellence (SOCE) franchise and implant business. Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Shalby reports consolidated net loss of Rs 1.81 crore in the December 2024 quarter

Net loss of Shalby reported to Rs 1.81 crore in the quarter ended December 2024 as against net profit of Rs 19.07 crore during the previous quarter ended December 2023. Sales rose 27.58% to Rs 275.63 crore in the quarter ended December 2024 as against Rs 216.05 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales275.63216.05 28 OPM %12.3019.59 - PBDT28.6743.21 -34 PBT12.3530.81 -60 NP-1.8119.07 PL Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Shalby to convene board meeting

Shalby will hold a meeting of the Board of Directors of the Company on 3 February 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Shalby gains on USFDA clearance for knee replacement device

Duraniom is the company's primary total knee replacement device with TiNbN coating. Based on the safety and effectiveness data, the US drug regulator has determined the device is substantially equivalent to legally marketed predicate devices. Shalby is the largest chain of multi-specialty hospitals in Western and Central India. It was founded by arthroplasty specialist, Dr. Vikram Shah. It performs more than 14,000 joint replacement surgeries a year and in the last 29 years has performed more than 1,45,000 joint replacements. It operates under three main verticals, namely, hospital business, Shalby Orthopedics Centre of Excellence (SOCE) franchise and implant business. The company's consolidated net profit dropped 87.71% to Rs 3.39 crore despite 12.42% increase in revenue from operations to Rs 267.53 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Shalby consolidated net profit declines 87.71% in the September 2024 quarter

Net profit of Shalby declined 87.71% to Rs 3.39 crore in the quarter ended September 2024 as against Rs 27.58 crore during the previous quarter ended September 2023. Sales rose 12.42% to Rs 267.54 crore in the quarter ended September 2024 as against Rs 237.98 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales267.54237.98 12 OPM %12.2022.15 - PBDT30.5554.93 -44 PBT13.7042.63 -68 NP3.3927.58 -88 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Shalby to hold AGM

Shalby announced that the 20th Annual General Meeting (AGM) of the company will be held on 26 September 2024.Powered by Capital Market - Live

6 months agoCapital Market - Live

Shalby jumps on bagging 30-year lease for Asha Parekh Hospital

7 months agoBusiness Standard
Shalby Buzzing In Trade After It Signs 30-year lease for Asha Parekh Hospital in Mumbai | CNBC TV18
7 months agoCNBC-TV18

Shalby consolidated net profit declines 29.24% in the June 2024 quarter

8 months agoBusiness Standard

Frequently asked questions

  1. What is the share price of Shalby Ltd (SHALBY) today?

    The share price of SHALBY as on 11th March 2025 is ₹199.13. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Shalby Ltd (SHALBY) share?

    The past returns of Shalby Ltd (SHALBY) share are
    • Past 1 week: 6.80%
    • Past 1 month: -5.46%
    • Past 3 months: -18.55%
    • Past 6 months: -29.19%
    • Past 1 year: -16.66%
    • Past 3 years: 52.82%
    • Past 5 years: 157.61%

  3. What are the peers or stocks similar to Shalby Ltd (SHALBY)?
  4. What is the dividend yield % of Shalby Ltd (SHALBY) share?

    The current dividend yield of Shalby Ltd (SHALBY) is 0.59.

  5. What is the market cap of Shalby Ltd (SHALBY) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Shalby Ltd (SHALBY) is ₹2176.58 Cr as of 11th March 2025.

  6. What is the 52 week high and low of Shalby Ltd (SHALBY) share?

    The 52-week high of Shalby Ltd (SHALBY) is ₹325 and the 52-week low is ₹180.35.

  7. What is the PE and PB ratio of Shalby Ltd (SHALBY) stock?

    The P/E (price-to-earnings) ratio of Shalby Ltd (SHALBY) is 25.89. The P/B (price-to-book) ratio is 2.16.

  8. Which sector does Shalby Ltd (SHALBY) belong to?

    Shalby Ltd (SHALBY) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.

  9. How to buy Shalby Ltd (SHALBY) shares?

    You can directly buy Shalby Ltd (SHALBY) shares on Tickertape. Simply sign up, connect your demat account and place your order.